BR112018014769A2 - ?composto, composição farmacêutica, e, método para tratamento do eczema nas mãos? - Google Patents

?composto, composição farmacêutica, e, método para tratamento do eczema nas mãos?

Info

Publication number
BR112018014769A2
BR112018014769A2 BR112018014769-9A BR112018014769A BR112018014769A2 BR 112018014769 A2 BR112018014769 A2 BR 112018014769A2 BR 112018014769 A BR112018014769 A BR 112018014769A BR 112018014769 A2 BR112018014769 A2 BR 112018014769A2
Authority
BR
Brazil
Prior art keywords
hands
compound
pharmaceutical composition
treating eczema
eczema
Prior art date
Application number
BR112018014769-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Wennberg Tero
Per Sørensen Anders
Original Assignee
Leo Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55236207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018014769(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leo Pharma A/S filed Critical Leo Pharma A/S
Publication of BR112018014769A2 publication Critical patent/BR112018014769A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Storage Of Fruits Or Vegetables (AREA)
BR112018014769-9A 2016-01-21 2017-01-20 ?composto, composição farmacêutica, e, método para tratamento do eczema nas mãos? BR112018014769A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16152215.6 2016-01-21
EP16152215 2016-01-21
PCT/EP2017/051133 WO2017125523A1 (en) 2016-01-21 2017-01-20 Treatment of hand eczema

Publications (1)

Publication Number Publication Date
BR112018014769A2 true BR112018014769A2 (pt) 2018-12-11

Family

ID=55236207

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018014769-9A BR112018014769A2 (pt) 2016-01-21 2017-01-20 ?composto, composição farmacêutica, e, método para tratamento do eczema nas mãos?

Country Status (31)

Country Link
US (3) US20200397787A1 (cg-RX-API-DMAC10.html)
EP (2) EP4257205A3 (cg-RX-API-DMAC10.html)
JP (1) JP6929860B2 (cg-RX-API-DMAC10.html)
KR (2) KR20180102662A (cg-RX-API-DMAC10.html)
CN (3) CN117159553A (cg-RX-API-DMAC10.html)
AU (3) AU2017209932A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018014769A2 (cg-RX-API-DMAC10.html)
CA (1) CA3010547A1 (cg-RX-API-DMAC10.html)
CY (2) CY1126388T1 (cg-RX-API-DMAC10.html)
DK (1) DK3405197T3 (cg-RX-API-DMAC10.html)
ES (1) ES2963784T3 (cg-RX-API-DMAC10.html)
FI (2) FI3405197T3 (cg-RX-API-DMAC10.html)
FR (1) FR24C1053I2 (cg-RX-API-DMAC10.html)
HR (1) HRP20231448T1 (cg-RX-API-DMAC10.html)
HU (2) HUE064192T2 (cg-RX-API-DMAC10.html)
IL (4) IL320757A (cg-RX-API-DMAC10.html)
LT (2) LT3405197T (cg-RX-API-DMAC10.html)
MX (2) MX394358B (cg-RX-API-DMAC10.html)
NL (1) NL301306I2 (cg-RX-API-DMAC10.html)
NO (1) NO2024058I1 (cg-RX-API-DMAC10.html)
PL (1) PL3405197T3 (cg-RX-API-DMAC10.html)
PT (1) PT3405197T (cg-RX-API-DMAC10.html)
RS (1) RS64798B1 (cg-RX-API-DMAC10.html)
RU (1) RU2018130097A (cg-RX-API-DMAC10.html)
SG (2) SG10202006830WA (cg-RX-API-DMAC10.html)
SI (1) SI3405197T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202300415T1 (cg-RX-API-DMAC10.html)
TW (2) TWI783921B (cg-RX-API-DMAC10.html)
UA (1) UA123780C2 (cg-RX-API-DMAC10.html)
WO (1) WO2017125523A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201804098B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3968997T3 (fi) * 2019-05-15 2026-06-09 Leo Pharma As Delgositinibin formulaatio voiteen muodossa
CA3210150A1 (en) * 2021-02-02 2022-08-11 Pfizer Inc. Dosing regime for treatment of chronic hand eczema
KR20240027044A (ko) * 2021-07-30 2024-02-29 일라이 릴리 앤드 캄파니 바리시티닙을 사용한 손 습진의 치료
JP2026509302A (ja) 2023-03-17 2026-03-17 レオ ファーマ アクティーゼルスカブ 中等症ないし重症の慢性手湿疹を有する患者における慢性手湿疹を処置する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US20130302298A1 (en) * 2010-11-30 2013-11-14 Bio-K Plus International Inc. Treatment and prevention of eczema
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent

Also Published As

Publication number Publication date
FR24C1053I1 (fr) 2025-02-21
WO2017125523A1 (en) 2017-07-27
SG11201805394QA (en) 2018-08-30
TW201736382A (zh) 2017-10-16
RU2018130097A (ru) 2020-02-21
CN117159554A (zh) 2023-12-05
JP2019502734A (ja) 2019-01-31
MX2018008449A (es) 2018-08-09
TWI841027B (zh) 2024-05-01
US20200397787A1 (en) 2020-12-24
HUS2400045I1 (hu) 2025-01-28
US20230138114A1 (en) 2023-05-04
SG10202006830WA (en) 2020-08-28
AU2022252766B2 (en) 2024-08-29
CY2024037I1 (el) 2026-02-25
JP6929860B2 (ja) 2021-09-01
EP3405197A1 (en) 2018-11-28
CN117159553A (zh) 2023-12-05
FIC20240048I1 (fi) 2024-12-19
AU2024266962A1 (en) 2024-12-19
KR20180102662A (ko) 2018-09-17
AU2017209932A1 (en) 2018-07-05
NO2024058I1 (no) 2024-12-13
UA123780C2 (uk) 2021-06-02
ZA201804098B (en) 2024-10-30
HUE064192T2 (hu) 2024-02-28
EP4257205A2 (en) 2023-10-11
NL301306I2 (nl) 2024-12-30
IL260094A (en) 2018-07-31
US20260216193A1 (en) 2026-07-30
LTPA2024538I1 (cg-RX-API-DMAC10.html) 2025-01-10
HRP20231448T1 (hr) 2024-03-01
CN108472297A (zh) 2018-08-31
RU2018130097A3 (cg-RX-API-DMAC10.html) 2020-05-25
TW202332451A (zh) 2023-08-16
EP4257205A3 (en) 2023-12-20
CY1126388T1 (el) 2026-02-25
IL297379A (en) 2022-12-01
NZ743582A (en) 2024-12-20
IL313543A (en) 2024-08-01
LT3405197T (lt) 2023-11-27
CY2024037I2 (el) 2026-02-25
PL3405197T3 (pl) 2024-02-12
EP3405197B1 (en) 2023-09-06
FR24C1053I2 (fr) 2025-12-05
AU2022252766A1 (en) 2022-11-03
IL320757A (en) 2025-07-01
SI3405197T1 (sl) 2024-03-29
CA3010547A1 (en) 2017-07-27
RS64798B1 (sr) 2023-11-30
FI3405197T3 (fi) 2023-11-23
KR20250088666A (ko) 2025-06-17
ES2963784T3 (es) 2024-04-02
TWI783921B (zh) 2022-11-21
PT3405197T (pt) 2023-12-06
SMT202300415T1 (it) 2024-01-10
MX2022005915A (es) 2022-06-27
MX394358B (es) 2025-03-24
DK3405197T3 (da) 2023-11-27

Similar Documents

Publication Publication Date Title
CO2017001035A2 (es) “2-(morfolin-4-il)-1,7-naftiridinas sustituidas, composiciones y combinaciones farmacéuticas que las comprenden, y compuestos intermediarios
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
CL2016000313A1 (es) Compuestos de benzoxaborol tricíclicos y usos de los mismos
NI201500118A (es) Imidazopiridazinas sustituidas
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
BR112015027440A2 (pt) DERIVADO DE [1,2,4]TRIAZOL[4,3-a]PIRIDINA, MÉTODO DE PREPA-RAÇÃO OU APLICAÇÃO MÉDICA DO DERIVADO
UY37973A (es) Derivados de indol macrocíclicos
UY37250A (es) Derivados macrocíclicos de indol
DOP2016000007A (es) Pirazolpiridinas sustituidas
CY1126388T1 (el) Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
UY37972A (es) Derivados de indol macrocíclicos sustituidos con cloro
MX2019001225A (es) Compuesto aromatico heterociclico nitrogenoso, metodo de preparacion del mismo, composicion farmaceutico del mismo y aplicacion del mismo.
BR112015023078A2 (pt) inibidores de pirrolopirimindina cdk9 quinase
BR112018005771A2 (pt) composto, agente terapêutico ou preventivo, uso de um composto, composição farmacêutica, e, método para tratamento de alopecia areata.
MX2021012874A (es) Tratamiento del lupus eritematoso cutaneo.
DOP2019000099A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos
BR112012027660A2 (pt) derivados de imidazo[1,2-a]piridina
BR112018012110A2 (pt) uso de derivados duplos de di-hidroisoquinolínio para o tratamento de materiais de queratina, composições e processos de implementação
BR112016024510A2 (pt) ?medicamento, uso de brexpiprazol ou de um sal farmaceuticamente aceitável do mesmo, métodos para prevenção ou tratamento de um transtorno relacionado com substância e para produção de uma composição farmacêutica, composição farmacêutica, e, kit?
PE20142020A1 (es) Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
PY1773438A (es) Método para producir una composición farmacéuticamente estable presentada como una solución acuosa

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]